

Investor Presentation


January 2025

Forward Looking Statements

This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex[®] Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause act ual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in reports filed by Anavex Life Sciences Corp. with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Anavex Life Sciences Corp. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Anavex Life Sciences Corp. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Anavex Life Sciences Corp. will obtain regulatory approval for any "phase" of clinical trials. We also cannot be sure of the clinical outcome for efficacy or safety of our compounds. Potential investors should refer to the risk factors in our reports filed on Edgar.



We are Dedicated to Pushing the Boundaries of Scientific Discovery With Novel Oral Small Molecules Tailored to Potentially Offer Hope and Relief.



Worldwide Alzheimer's - Dementia Cases Projected to Grow to Over 130M by 2050

We believe we are positioned to capitalize on a significant and growing market opportunity to treat CNS diseases

>\$20T Cumulative costs of Alzheimer's and dementia care from 2015 to 2050


1 in 3

Medicare dollars will be spent on people living with Alzheimer's and other dementias in 2050


>11M The number of Americans providing unpaid care for people with Alzheimer's or other dementias

Targeting these markets using a differentiated and transformative precision platform

PEOPLE LIVING WITH **DEMENTIA** AROUND THE WORLD



Anavex Investment Highlights



Wide international patent protection for product candidates



Estimated that operations and clinical programs are funded for 4 years. No debt

Regulatory submission stage CNS Precision Medicine platform Company

Meet with regulatory authorities to discuss full Phase 2b/3 Alzheimer's data with aim to bring Alzheimer's therapy to patients in Europe, Asia-Pacific, and

the U.S., including potential approval pathway based on available efficacy

with novel central nervous system mechanism

results of surrogate biomarkers

Ų

Oral drug Blarcamesine demonstrated superior clinical safety and efficacy compared to mAb Leqembi (Lecanemab) and mAb Kisunla (Donanemab) and slows neurodegeneration in Early Alzheimer's Disease^{1,2,3}

Blarcamesine: Oral once daily convenient scalable treatment

- 1. https://www.anavex.com/post/anavex-sphase2b-3trialofblarcamesine-anavex-2-73-inpatientswithalzheimer-sdisease
- 2. van Dyck CH et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023; 388(1): 9–21
- 3. Sims JR et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; 330(6): 512–27



Foundation for More Cost Effective & Safer Treatments for CNS Conditions

Oral Solid ANAVEX[®]2-73 (blarcamesine)

- Alzheimer's Disease
- Parkinson's Disease
- Parkinson's Disease Dementia



Oral Liquid ANAVEX[®]2-73 (blarcamesine)

- Rett Syndrome
- Fragile X Syndrome
- Infantile Spasms
- Angelman Syndrome



Oral Solid ANAVEX®3-71 (AF710B)

- Schizophrenia
- Frontotemporal Dementia (FTD)
- Alzheimer's Disease



Orally-administered candidates offer significant potential for clinical benefit relative to costly and logistically challenging biologic mAb-based drugs, which also often present additional safety challenges

1. Prasad V., De Jesús K., Mailankody S. (2017). The high price of anticancer drugs: origins, implications, barriers, solutions. Nat. Rev. Clin. Oncol. 14 (6), 381. 10.1038/nrclinonc.2017.31



~60%

of established small-molecule drug products available commercially are administered orally¹

~90%

of the global market share of all pharmaceutical formulations for humans are oral¹

~84%

of the best-selling pharmaceutical products are orally administered¹

Wanavex

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities



Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration



Multiple clinical milestones and promising pipeline with potential progress towards commercialization



Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease



We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government



Anavex Precision Platform Enables a Novel Approach

Targeting CNS conditions with precision and restoring neuronal homeostasis via SIGMAR1 activation

Proprietary SIGMACEPTOR[™] Discovery Platform produces small molecule therapeutic candidates for targeting the SIGMAR1 receptor

Age- and chronic related Changes

Chronic CNS pathologies, including progressive chronic Alzheimer's, cause exhaustion of the body's own SIGMAR1 activators, impairing the body's response to chronic cellular stress

Progressive CNS Pathology (e.g., AD, PD)

Impaired body-own compensatory SIGMAR1 response to chronic cellular stress

ANAVEX®2-73 (blarcamesine)

ANAVEX[®]2-73 (blarcamesine) re-establishes the body's own SIGMAR1 response and restores SIGMAR1 levels Beneficial therapeutic effect for patients

SIGMAR1 target binding affinity is so specific that even when patients carry a variant receptor, still powerful effects observed. All patients regardless of genotype stand to benefit



Christ, MG, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. *Cells*. 2019;8(3):211. Yang H, et al. SIGMAR1/sigma-1 receptor ablation impairs autophagosome clearance. *Autophagy*. 2019;15(9):1539-1557. Lee JH, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. *Nature Neuroscience*. 2022;25(6):688-701.




9



Christ, MG, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. *Cells*. 2019;8(3):211. Yang H, et al. SIGMAR1/sigma-1 receptor ablation impairs autophagosome clearance. *Autophagy*. 2019;15(9):1539-1557. Lee JH, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. *Nature Neuroscience*. 2022;25(6):688-701.






Christ, MG, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. Cells. 2019;8(3):211.

Yang H, et al. SIGMAR1/sigma-1 receptor ablation impairs autophagosome clearance. Autophagy. 2019;15(9):1539-1557.

Lee JH, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nature Neuroscience. 2022;25(6):688-701.






Christ, MG, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. Cells. 2019;8(3):211.

Yang H, et al. SIGMAR1/sigma-1 receptor ablation impairs autophagosome clearance. Autophagy. 2019;15(9):1539-1557.

Lee JH, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nature Neuroscience. 2022;25(6):688-701.





Christ, MG, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. Cells. 2019;8(3):211.

Yang H, et al. SIGMAR1/sigma-1 receptor ablation impairs autophagosome clearance. Autophagy. 2019;15(9):1539-1557.

Lee JH, et al. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nature Neuroscience. 2022;25(6):688-701.



Precision Platform Shows Promise for Superior Care

We believe Anavex is positioned to target significant unmet medical needs across multiple CNS conditions



SIGMAR1 activation established as a new platform class

- ANAVEX[®]2-73 (blarcamesine) Clinical study results in broad CNS indications confirm SIGMAR1 technology
- Rett syndrome: Top-line data EXCELLENCE Phase 2/3 ANAVEX[®]2-73 pediatric clinical trial
- ANAVEX[®]3-71: Publication Phase 1 clinical $\overline{}$ trial
- Parkinson's disease dementia: Data of 48week OLE Phase 2 study
- Alzheimer's disease: Top-line data ANAVEX[®]2-73-AD-004: Potentially pivotal Phase 2b/3 clinical trial
- Schizophrenia: Initiation of ANAVEX[®]3-71 Phase 2 clinical trial

https://doi.org/10.1016/i.jphs.2014.12.005

÷ • •	Near	lern
×	Itour	

SIGMAR1 technology to succeed traditional modalities

- Alzheimer's disease: Full regulatory submission of blarcamesine in Europe (EMA)
- Alzheimer's disease: Data from the blarcamesine Phase 2b/3 ANAVEX[®]2-73-AD-004 trial to be published in an upcoming peer-reviewed journal expected Q1 2025
- Alzheimer's disease: Analysis of RNA sequencing (RNAseq) of the Phase 2b/3 data expected 2025
- Alzheimer's disease: ATTENTION-AD OLE 96/144-week Top-line trial data January 2025
- Schizophrenia: Top-line data of ANAVEX[®]3-71 Phase 2 clinical trial expected 2025
- **Parkinson's disease:** Initiation of ANAVEX[®]2-73 imagingfocused trial or Phase 2b/3 >6 months trial
- Fragile X: Initiation of ANAVEX[®]2-73 Phase 2/3 clinical trial
- New Rare disease: Initiation of ANAVEX[®]2-73 Phase 2/3 clinical trial
- Publications: Continued clinical publications involving ANAVEX[®]2-73 and ANAVEX[®]3-71
- 1 K. Ruscher, T. Wieloch, The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration, Journal of Pharmacological Sciences, Volume 127, Issue 1, 2015, Pages 30-35, ISSN 1347 8613. https://doi.org/10.1016/i.jphs.2014.11.011.





Expanded CNS indications

ong Term

- Regenerative medicine¹
- Disease prevention²

We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities



Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration



Multiple clinical milestones and promising pipeline with potential progress towards commercialization



Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease



We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government



Multiple Clinical Milestones and Promising Pipeline with Potential Progress towards Commercialization

CANDIDATE	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	PHASE OLE	
ANAVEX [®] 2-73	ALZHEIMER'S DISEASE		AD ANAVEX [®] 2-73-AD-004		AD ANAVEX [®] 2-73-AD-004 OLE	
blarcamesine	PARKINSON'S DISEASE DEMI	ENTIA	ANAVEX [®] 2-73-PDD-001			
THE MICHAELA FOR FOUNDATION FOR PARENDOW'S RESEARCH	PARKINSON'S DISEASE		ANAVEX [®] 2-73-PET-001	ANAVEX [®] 2-73-PD-001		
Constantional Ref Syndrome Foundation	*RETT SYNDROME		EXCELLENCE ANAVEX [®] 2-73-RS-003	EXCELLENCE ANAVEX®2-73-RS-003		
C International Reff Syndrome Foundation			AVATAR ANAVEX [®] 2-73-RS-002	AVATAR ANAVEX®2-73-RS-002		
C International Reff Syndrome Foundation			ANAVEX [®] 2-73-RS-001	Fast Trac	k, Rare Pediatric, Orphan Drug (U.S./EU)	
	UNDISCLOSED RARE DISEAS	E				
FRAXA	*FRAGILE X					
FAST Venter **elected	ANGELMAN'S					
	*INFANTILE SPASMS					
ANAVEX®3-71	SCHIZOPHRENIA	ANAVEX®3-71-001	ANAVEX®3-71-SZ-001			
AF710B	*FRONTOTEMPORAL DEMENTIA (FTD)	ANAVEX®3-71-001				
	ALZHEIMER'S DISEASE	ANAVEX®3-71-001				
ANAVEX®1-41	DEPRESSION				Legend	
	STROKE				Solid color = completed	
	NEURODEGENERATIVE DIS EASES				Gradient color = ongoing	
ANAVEX®1066	VISCERAL PAIN				Dashed lines = planned	
	ACUTE & NEUROPATHIC PAIN	I			OLE = Open Label Extension	



16

Mana

Treating Alzheimer's Disease (AD)

Progressive, neurological disease and the most common cause of dementia in humans¹

- Progressive development; slowly destroys memory and thinking skills in people
- **Impacts families** and nearly **every aspect** of a person's life as it progresses: short-term memory loss and confusion, difficulty learning new things, delusions and disorientation, inability to recognize common things in people
- Current annual cost of dementia is estimated at \$1T, a figure set to double by 2030



~35M people worldwide living with AD²

~6.9M people in the U.S. living with AD²




CANDIDATE **STAGE 1** STAGE 2 **STAGE 3 STAGE OLE** ANAVEX[®]2-73 \checkmark (blarcamesine) AD ANAVEX[®]2-73-004 ANAVEX®2-73-001 AD ANAVEX[®]2-73-002/3 (Ongoing EMA) ANAVEX®3-71 ANAVEX®3-71-001 (Planned Trial) Source: www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia

2. Sources available on slide 28 of this presentation.

Treating Parkinson's Disease (PD) & Parkinson's Disease Dementia (PDD)

Motor disorder in which patients suffer from tremors in their extremities and head, stiff limbs and inability to relax muscles during episodes

- Up to 80% of those with Parkinson's disease (PD) eventually experience Parkinson's disease dementia¹
- Progressive development; can cause numerous cognitive and behavioral deficits
- Parkinson's disease is a fairly common neurological disorder in older adults, estimated to affect nearly 2% of those over the age of 65



>1% of the world population has PD²

CANDIDATE **STAGE 1 STAGE 2 STAGE 3** ANAVEX[®]2-73 PARKINSON'S DISEASE (blarcamesine) ANAVEX®2-73-001 (Planned Trial) (Planned Trial) **PARKINSON'S** ANAV/FX[®]2-73 DISEASE (blarcamesine) ANAVEX[®]2-73-001 PDD ANAVEX®2-73-PDD-001 (Planned Trial) DEMENTIA

 Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017 Apr;13(4):217-231. doi: 10.1038/nrneurol.2017.27. Epub 2017 Mar 3. PMID: 28257128; PMCID: PMC5643027;
www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/parkinson-s-disease-dementia >**1.5M** Americans affected by PD today²



Treating Rett Syndrome

Neuro-developmental disease in girls with both movement impairment and cognitive impairment¹

- Second most common cause of severe intellectual disability in females
- Cognitive and motor delays begin to manifest along with slower head growth following relatively normal infancy (~1.5 to 3 years of age, loss of spoken language, and hand skills begin to develop)
- Associated with four key symptoms: loss of expressive language, loss of fine motor skills, impaired ability to walk and repetitive hand movement





~350,000 patients diagnosed with Rett Syndrome worldwide¹

patients diagnosed with Rett Syndrome in the U.S.²

Manave

~11,000

Real World Evidence (RWE): Patients with Rett Syndrome Positive Feedback with Blarcamesine

Voice of the Patients: Real World Evidence (RWE)

- Brigitte: "<u>We did get a surprise once with her mobility. We heard a noise from our family room, and next we</u> looked, and Madeline had climbed twelve steps upstairs to her bedroom by herself."
- Jayne: "<u>Within a week of starting the Anavex open label extension, she only had one seizure and then she went</u> <u>three months without a seizure.</u>"
- See related link for more video comments from parents at <u>RSAA/parent stories</u>.
- >91% of patients completing the EXCELLENCE trial continued into a 48-week open-label extension study (OLE)
- To date, of the pediatric patients who completed the OLE, 93% have joined the Compassionate Use Program
- Compassionate Use level for adult patients from AVATAR trial after 48-week OLE is >96%
- As of today, some patients with Rett syndrome have been on blarcamesine-treatment for >4 years, combined OLE and Compassionate Use Program



We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities



Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration



Multiple clinical milestones and promising pipeline with potential progress towards commercialization



Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease



We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation




Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government



AD-004 Phase 2b/3 Early Alzheimer's Disease Trial

Global, multicenter, randomized, double-blind, placebo-controlled, parallel group, 48-week trial evaluating Blarcamesine (ANAVEX[®]2-73) once-daily oral capsules



1. AD status supported by the elevated baseline levels of plasma p-Tau(181) and p-Tau(231)


2. Titration occurred from days 1-21

AD, Alzheimer's disease; ADAS-Cog13, a 13-item cognitive subscale of the Alzheimer's Disease Assessment Scale; ADCS-ADL, AD Cooperative Study-Activities of Daily Living Scale; CDR-SB, Clinical Dementia Rating-Sum of Boxes; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NIA-AA, National Institute on Aging- Alzheimer's Association. Nf-L, neurofilament light chain.



Alzheimer's Disease Pathology Manifested in Brain Volume Loss (Atrophy) of the Brain

Brain volume loss (atrophy) in Alzheimer's disease (AD)¹




NORMAL





Reduced Atrophy of the Brain in Blarcamesine-treated Patients Compared to Placebo


Significant slowing of atrophy in broad brain regions after 48 weeks of treatment¹





ATTENTION-AD AD-004 OLE Phase IIb/III Early Alzheimer's Disease

Global, multicenter, randomized, Open-Label-Extension (OLE), 96/144-week trial evaluating Blarcamesine (ANAVEX[®]2-73) once-daily oral capsules, following placebo-controlled 48-week trial¹



25

1. The preceding double-blind study (ANAVEX®2-73-AD-004) had started in Australia before the other regions (Europe and North America). This did not allow time for the other regions to also participate in the additional OLE extension beyond the initial 96 Weeks OLE period, which was extended to 144 Weeks upon investigators request in Australia.

2. The scheduled visits were [OLE Week 0 = Combined Week 48], [OLE Week 48 = Combined Week 96], [OLE Week 96 = Combined Week 144] and [OLE Week 144 = Combined Week 192]; Combined = OLE (open-label-extension) + DB (double-blind) studies.

Delayed-Start Analysis ATTENTION-AD and AD-004 Trial

Top-line data:

Key safety findings	Key efficacy findings	Summary
• No new safety findings observed with blarcamesine	Treatment LS mean difference continued to increase up to Week 192:	Suggests earlier blarcamesine treatment initiation may
over four (4) years	ADAS-Cog13 difference: -3.83	have continued
There were no	<i>P</i> = 0.0165	long-term beneficial
deaths related to the study drug	• ADCS-ADL difference: +4.30 P = 0.0206)	therapeutic effect

ADAS-Cog13 difference larger than 2 points are considered clinically meaningful improvements* Manavex

26

* Muir RT, Hill MD, Black SE, Smith EE. Minimal clinically important difference in Alzheimer's disease: Rapid review. Alzheimers Dement. 2024;20(5):3352-3363. doi:10.1002/alz.13770

P = 0.0206)

Anavex's Blarcamesine Advantage:

✓ Oral administration

✓ Novel target that impacts neurodegeneration

✓ Promising clinical results

The Journal of Prevention of Alzheimer's Disease 12 (2025) 100016



Contents lists available at ScienceDirect

The Journal of Prevention of Alzheimer's Disease

journal homepage: www.elsevier.com/locate/tjpad

Original Article

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

Stephen Macfarlane^a, Timo Grimmer^b, Ken Teo^a, Terence J O'Brien^c, Michael Woodward^d, Jennifer Grunfeld^e, Alastair Mander^f, Amy Brodtmann^g, Bruce J. Brew^h, Philip Morrisⁱ, Cathy Short^j, Susan Kurrle^k, Rosalyn Lai^l, Sneha Bharadwaj^m, Peter Drysdaleⁿ, Jonathan Sturm^o, Simon J.G. Lewis^p, David Barton^q, Chris Kalafatis^r, Saif Sharif³, Richard Perry^t, Nicholas Mannering^u, J.Emer MacSweeney^v, Stephen Pearson^w, Craig Evans^x, Vivek Krishna^y, Alex Thompson^z, Malathy Munisamy^{aa}, Neel Bhatt^{bb}, Aliya Asher^{cc}, Sandra Connell^{dd}, Jennifer Lynch^{ee}, Sterre Malou Rutgers^{ff}, Paul LJ Dautzenberg⁸⁸, Niels Prins^{hh}, Patrick Oschmannⁱⁱ, Lutz Frölich^{jj}, Pawel Tacik^{kk}, Oliver Peters^{II}, Jens Wiltfang^{mm}, Alexandre Henri-Bhargavaⁿⁿ, Eric Smith^{oo}, Stephen Pasternak^{PP}, Andrew Frank^{qq}, Howard Chertkow^{rr}, Jennifer Ingram^{ss}, Ging-Yuek Robin Hsiung^{II}, Rodney Brittain^{uu}, Carmela Tartaglia^{vv}, Sharon Cohen^{ww}, Luca M Villa^{xx}, Elizabeth Gordon^{xx}, Thomas Jubault^{yy}, Nicolas Guizard^{yy}, Amanda Tucker^{zz}, Walter E Kaufmann^{zz}, Kun Jin^{zz},



JPA1

C.D

Check for updates We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities



Precision medicine platform and novel central nervous system mechanism: Activation of an upstream, endogenous pathway countering neurodegeneration



Multiple clinical milestones and promising pipeline with potential progress towards commercialization



Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease



We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation




Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government



Exploring Commercial Activities

Examining innovative strategies to effectively engage patients, providers and payers







High demand from Alzheimer's disease patients and families for easy access and scalable treatment options

Intended to reduce the need for complex procedures for the treatment of people with Alzheimer's disease

Blarcamesine **orally once daily** versus challenges of biologic mAb-based intravenous drug

Wanavex

29

Addressable CNS Diseases Globally with Therapeutic Disruption Potential

U.S. AND GLOBAL PATIENT NUMBERS

INDICATION	USA	EUROPE	ASIA	GLOBAL
Alzheimer's Disease (AD) ^{1,2}	~6,900,000	~7,000,000	~23,000,000	~35,000,000
Parkinson's Disease (PD) ^{3,4}	~1,000,000	~1,400,000	~3,000,000	~10,000,000
Schizophrenia ^{5,6*}	~1,600,000	~3,000,000	~9,000,000	~24,000,000
Frontotemporal Dementia (FTD) ⁷	~60,000	~65,000	~500,000	~800,000
Rett Syndrome (RTT) ^{8*}	~11,000	~13,000	~37,000	~350,000
Fragile X Syndrome (FXS) ^{9,10*}	~62,500	~150,000	~900,000	~1,400,000

1. Alzheimer's Association. 2024 Alzheimer's Disease Facts and Figures

2. Dementia in the Asia Pacific Region. Alzheimer's Disease International 2014; 10

3. Marras C et al 2018. npj Parkinson's Disease volume 4, Article number: 21

4. GBD 2016 Parkinson's Disease Collaborators. The Lancet 2018 Volume 17, Issue 11, P3939-953

5. National Alliance on Mental Illness, 2019; Schizophrenia. World Health Organization. Accessed January 2024. https://www.who.int/news-room/fact-sheets/detail/schizophrenia

6. Fasseh et al., 2018. Eur J Public Health. 2018 Dec 1;28(6):1043-1049

7. Knopman & Roberts 2011. J Mol Neurosci 2011;45(3):330-335

8. Rettsyndrome.org, 2016

9. National Fragile X Foundation, 2022

10. Hunter et al., 2014. Am J Med Genet A. 2014 Jul;164A(7):1648-5

Manavex 30

* Patient estimates derived from the published prevalence estimate range for the regional population

Worldwide Commercial Rights to Capitalize on Valuable Pipeline and Global Opportunity

Aiming to bring lead therapies to patients in Europe, Asia-Pacific, and the U.S. following regulatory discussion



Wide international patent protection to 2030-2039 for product candidates



We believe we are well-Positioned to Expand Transformative Precision Medicine Platform & Capitalize on Significant Market Opportunities



Blarcamesine shows clinical efficacy and slows neurodegeneration in early Alzheimer's disease

Precision medicine platform and novel central nervous system

mechanism: Activation of an upstream, endogenous pathway countering

Multiple clinical milestones and promising pipeline with potential progress

V C

neurodegeneration

towards commercialization

We believe we are positioned for future expansion with worldwide commercial rights and strong IP foundation



Sufficient cash runway due to disciplined operations and non-dilutive cash sources, such as Michael J. Fox Foundation, International Rett Syndrome Foundation and The Australian Government



Anavex's Strong Financial Profile Supports Operations and Clinical Programs are Funded for 4 Years

trong balance sheet supported by non-dilutive	Disciplined approach to
unding sources	operational expenditures
<pre>\$132.2M</pre>	30.8M
Cash and cash equivalents ¹	Fiscal year 2024 cash utilization
✓ AB4M Shares outstanding ¹	Sufficient cash runway
Non-dilutive funding sources	Est. Years of Runway

operations and non-dilutive cash sources





Values-Driven Team with Track Record and Expertise Capable of Advancing Anavex's Cutting-Edge Precision Platform

Christopher U. Missling, PhD

President & CEO

20+ years of experience in the healthcare industry within large pharmaceutical companies, the biotech industry and investment banking



Juan Carlos Lopez-Talavera, MD, PhD

SVP Head of Research and Development

25+ years of key leadership in managing registrational clinical trials and led and contributed to the development and approvals of several treatments in USA, Europe and Asia

abbvie Ill Bristol Myers Squibb



Madrigal

medical affairs



Jeffrey Edwards, PhD

VP of Clinical Pharmacology

18+ years of drug development including clinical pharmacology and clinical science









Retrophin

Daniel Klamer, PhD

VP of Business Development & Scientific Strategy

15+ years of experience in neuroscience and the

orphan disease space, with acquisition, partnering

and R&D experience in Europe and the USA

NEUROSEARCH



27+ years of experience with US Food and Drug Administration (FDA)

Kun Jin, PhD

VP Head of Biostatistics

University of

Pittsburgh

leadership positions in clinical development, clinical operations, regulatory affairs, and

28+ years of experience in executive

Terrie Kellmeyer, PhD

SVP of Clinical Development

Purpose-Built Scientific Advisory Board

Diverse skillset tailored to Anavex's portfolio

叔

Ųø

CNS Drug development

Trial design and analysis

Academic and research thought leadership

Clinical expertise in treating CNS diseases

Andrew Cole, MD	Corinne Lasmezas, PhD	Dag Aarsland, MD, PhD
HARVARD MEDICAL SCHOOL	🚫 Scripps Research	KING'S College LONDON
Daniel Weintraub, MD	Jacqueline French, MD	Jeffrey Cummings, MD
School of Medicine UNIVERSITY OF PENNSYLVANIA	NYU	Cleveland Clinic
Norman Relkin, MD, PhD	Ottavio Arancio, MD, PhD	Paul Aisen, MD
Weill Cornell Medicine	Columbia University Medical Center	USC University of Southern California
Tangui Maurice, PhD	Timo Grimmer, MD	Marwan Sabbagh, MD
UNIVERSITÉ DE MONTPELLIER	Technische Universität München	Reurological Institute



Anavex's Advantage is Precision Medicine Platform Scalability

Equitable and Accessible for Diverse Populations, and Maintaining Sustainability within Global Healthcare Systems





Contact Us

Corporate Office

Anavex Life Sciences Corp. 630 5th Avenue, 20th floor New York, NY 10111

1-844-689-3939

Shareholder & Media Relations

ir@anavex.com www.anavex.com

NASDAQ: AVXL